Pegaptanib sodium injection is an anti-angiogenic medicine for the treatment of neovascular (wet) AMD. It was discovered by Gilead Sciences and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the US.
Avecia Biotechnology said that the agreement includes technology transfer, process validation and commercial supply of a key component of Macugen.
Detlef Rethage, president of Avecia Biotechnology, said: “The agreement with Pfizer to manufacture a key component of this commercial oligonucleotide-based therapeutic is testament to our experience, reliability and quality standards with regard to technology transfer, process validation and the manufacture of oligonucleotide drug substances.”